Skip to main content
APLM
NASDAQ Life Sciences

CFO Invests $400K in Private Placement, Boosting Insider Confidence

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$23.55
Mkt Cap
$51.717M
52W Low
$3.659
52W High
$42.12
52W Position info
544% above low
Off High info
44% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

APLM has more than doubled off its 52-week low of $3.659.

Summary

Apollomics' CFO, Peter Kuan-How Lin, purchased $400,005 worth of shares in a private placement, signaling strong insider confidence.


Key Events · Ownership and Investor Activity · APLM

  • CFO Investment

    CFO Peter Kuan-How Lin acquired 26,667 shares for $400,005 at $15.00 per share as part of a private placement.

  • Insider Conviction

    This purchase, representing a substantial portion of the company's market cap, follows recent significant investments by the CEO and a director-affiliated entity in the same private placement.

  • Context of Capital Raise

    The private placement, which raised $10 million, provides crucial capital for the company, especially after recently resolving a Nasdaq delisting notice.


Analysis · APLM · Life Sciences

Apollomics' Chief Financial Officer, Peter Kuan-How Lin, has invested $400,005 in the company's recent private placement at $15.00 per share. This significant personal investment, following a $5.55 million investment by the CEO and a $300,000 investment by a director-affiliated entity, demonstrates strong insider conviction in the company's prospects, especially after the recent resolution of a Nasdaq delisting threat.

How filings like this one have moved

In the 30 days to Sep 15, 2026, 40.7% of the 388 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, APLM was trading at $23.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.7M. The 52-week trading range was $3.66 to $42.12. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

APLM - Latest Insights

APLM
Aug 17, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $23.55
Real-time Price: $22.98 info
Change: -$0.570 (-2%) info
Market Cap: $66.986M info
APLM
Aug 11, 2026, 4:35 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.16
Real-time Price: $22.98 info
Change: +$4.82 (+27%) info
Market Cap: $66.986M info
APLM
Jul 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.95
Real-time Price: $22.98 info
Change: +$4.03 (+21%) info
Market Cap: $66.986M info
APLM
Jun 24, 2026, 6:28 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $20.50
Real-time Price: $22.98 info
Change: +$2.48 (+12%) info
Market Cap: $66.986M info
APLM
Jun 24, 2026, 5:11 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $20.50
Real-time Price: $22.98 info
Change: +$2.48 (+12%) info
Market Cap: $66.986M info